• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    11/14/24 6:59:16 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email
    SC 13G/A 1 ea022116104-13ga1vivo9_insti.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A
     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     
    Instil Bio, Inc.
    (Name of Issuer)
     
    Common stock, par value $ 0.000001 per share
    (Title of Class of Securities)
     
    45783C200
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 45783C200
    1 NAMES OF REPORTING PERSONS  
    Vivo Capital IX, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a) ☐
    (b) ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    585,485 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    585,485 (1)
    8 SHARED DISPOSITIVE POWER
    0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    585,485 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.0% (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    OO
             

    (1)The shares of common stock, par value $0.000001 per share (the “Common Stock”) of Instil Bio, Inc. (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P. as of October 31, 2024. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.
      
    (2) Based on 6,503,913 shares of Common Stock issued and outstanding as of August 9, 2024, as disclosed in the Issuer’s Quarterly Report on 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024.  

     

    2

     

     

    CUSIP No. 45783C200
    1 NAMES OF REPORTING PERSONS  
    Vivo Capital Fund IX, L.P.  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a) ☐
    (b) ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    585,485 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    585,485 (1)
    8 SHARED DISPOSITIVE POWER
    0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    585,485 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.0% (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    PN
             

    (1)The shares of Common Stock of the Issuer are held of record by Vivo Capital Fund IX, L.P. as of October 31, 2024. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.
      
    (2)Based on 6,503,913 shares of Common Stock issued and outstanding as of August 9, 2024, as disclosed in the Issuer’s Quarterly Report on 10-Q, filed with the SEC on August 13, 2024.

     

    3

     

     

    Item 1. (a) Name of Issuer:

     

    Instil Bio, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    3963 Maple Avenue, Suite 350

     

    Dallas, Texas 75219

     

    Item 2. (a)Name of Person Filing:

     

    Vivo Capital IX, LLC

     

    Vivo Capital Fund IX, L.P.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Vivo Capital IX, LLC, a Delaware limited liability company. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    Vivo Capital Fund IX, L.P., a Delaware limited partnership

     

    (d)Title of Class of Securities:

     

    Common stock, par value $0.000001 per share

     

    (e)CUSIP Number:

     

    45783C200

     

    Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act.

     

    (b)☐ Bank as defined in Section 3(a)(6) of the Act.

     

    (c)☐ Insurance company as defined in Section 3(a)(19) of the Act.

     

    (d)☐ Investment company registered under Section 8 of the Investment Company Act of 1940.

     

    (e)☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

     

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)☐ Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    4

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    All securities are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (b)Percent of class:

     

    9.0%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:
       
      585,485 shares

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of:
       
      585,485 shares

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Vivo Capital IX, LLC
       
      November 14, 2024
      (Date)
       
      /s/ Frank Kung
      (Signature)
       
      Managing Member
      (Title)

     

      Vivo Capital Fund IX, L.P.
       
      By: Vivo Capital IX, LLC, its General Partner
       
      November 14, 2024
      (Date)
       
      /s/ Frank Kung
      (Signature)
       
      Managing Member

     

    6

     

     

    EXHIBIT INDEX

     

    Exhibit    
    99.1   Joint Filing Statement

     

     

    7

     

     

    Get the next $TIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    8/13/2021$34.00Outperform
    Robert W. Baird
    8/13/2021$34.00Outperform
    Baird
    More analyst ratings

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:42 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO and Chairman Crouch Bronson

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:15 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      9/23/24 1:12:01 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, March 04, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("I

      3/4/25 7:09:26 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

      ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals DALLAS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceutica

      1/14/25 7:00:37 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a

      11/13/24 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

      11/14/22 4:07:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

      DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi

      9/6/22 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TIL
    SEC Filings

    See more
    • Instil Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:55 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Truist with a new price target

      Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:34 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Instil Bio

      JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform

      11/4/24 7:41:54 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Instil Bio Inc.

      DEFR14A - Instil Bio, Inc. (0001789769) (Filer)

      5/2/25 5:00:20 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Instil Bio Inc.

      DEFA14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Instil Bio Inc.

      DEF 14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:08 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 6:59:16 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 5:48:56 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      10/25/24 9:42:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care